Recent Updates
Recently added Catalysts
ELDN Positive Sentiment Score: 75/100

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Wednesday, July 30, 2025 2 min read
Key Takeaway: Eledon Pharmaceuticals will host a conference call on August 6, 2025, to discuss updated data from its Phase 1b trial of tegoprubart for preventing rejection in kidney transplant recipients. The data will be presented at the World Transplant Congress in San Francisco. Approximately 30 subjects are involved in the ongoing study.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eledon Pharmaceuticals is presenting updated clinical data at a major conference.
  • The ongoing Phase 1b trial shows promise for tegoprubart in kidney transplantation.
  • The company is focused on developing therapies for life-threatening conditions.

Full Press Release Details

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025.
To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conference ID is 34575. Registration for the live webcast can be foundhereand available on the “Events” section of Eledon’s website atwww.eledon.com. The webcast will be archived on the website following the completion of the call.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website atwww.eledon.com.
Follow Eledon Pharmaceuticals on social media:LinkedIn;Twitter

Investor Contact:

Stephen JasperGilmartin Group(858) 525 2047stephen@gilmartinir.com

Media Contact:

Jenna UrbanCG Life(212) 253 8881jurban@cglife.com
Source: Eledon Pharmaceuticals

Frequently Asked Questions

What is the purpose of the conference call?

The conference call will discuss updated clinical data from the Phase 1b trial of tegoprubart.

When will the conference call take place?

The conference call is scheduled for August 6, 2025, at 4:30 p.m. ET.

Where will the data be presented?

The data will be presented at the World Transplant Congress in San Francisco.

How many subjects are involved in the study?

Approximately 30 kidney transplant recipients are participating in the study.

Tags: ELDN Viatris Investor Conferences Healthcare Eledon Pharmaceuticals tegoprubart kidney transplantation Phase 1b trial World Transplant Congress
Last updated: Jul 30, 2025